Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

Share Price Information for polarean (POLX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.75
Bid: 3.70
Ask: 3.80
Change: -0.25 (-6.25%)
Spread: 0.10 (2.703%)
Open: 4.00
High: 3.95
Low: 3.75
Prev. Close: 4.00
POLX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing six monthly return

27 Jan 2023 07:00

RNS Number : 0081O
Polarean Imaging PLC
27 January 2023
 

 

Polarean Imaging Plc

("Polarean" or the "Company")

 

Block Listing Six Monthly Return

 

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

 

Name of applicant:

Polarean Imaging Plc

Name of scheme:

Polarean Share Option Plan

Number and class of securities originally admitted:

8,000,000 ordinary shares of £0.00037 each

Date of admission:

29 July 2021

Period of return:

From:

28 July 2022

To:

26 January 2023

Balance of unallotted securities under scheme(s) from previous return:

4,025,657

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

 

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

 

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

4,025,657

Total number of securities in issue at the end of the period

213,047,509

 

Name of contact:

Richard Hullihen, Chief Executive Officer

Telephone number of contact:

+ 44 (0)20 7933 8780 or polarean@walbrookpr.com

 

 

 

 

Enquiries:

 

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Kenneth West, Chairman

 

 

Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)

+44 (0)20 7710 7600

Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)

Nick Adams / Nick Harland (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com

Anna Dunphy /Phillip Marriage

Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082

 

About Polarean (www.polarean.com)

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung function, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform, Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On December 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEWTM (xenon Xe 129 hyperpolarized). 129Xe MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

 

XENOVIEWTM is a trademark of Polarean, Inc. POL-PR-2201

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRNKABQNBKDFDB
Date   Source Headline
12th Oct 20212:00 pmRNSPrice Monitoring Extension
11th Oct 20219:05 amRNSSecond Price Monitoring Extn
11th Oct 20219:00 amRNSPrice Monitoring Extension
11th Oct 20217:00 amRNSSystem installation
11th Oct 20217:00 amRNSDirector dealings
6th Oct 20214:40 pmRNSSecond Price Monitoring Extn
6th Oct 20214:35 pmRNSPrice Monitoring Extension
6th Oct 20212:03 pmRNSComplete Response Letter received from FDA
24th Sep 20217:00 amRNSTransfer of warrants
3rd Sep 20217:00 amRNSHolding(s) in Company
2nd Sep 20217:00 amRNSHalf-year Report
31st Aug 20217:00 amRNSTotal Voting Rights
23rd Jul 20219:29 amRNSBlock listing application
13th Jul 20212:26 pmRNSResult of AGM
9th Jul 20217:00 amRNSGrant of Options & Director Compensation Reduction
7th Jul 20217:00 amRNSNew System Installation
4th Jun 20217:00 amRNSFinal Results
26th May 20217:00 amRNSArticle on hyperpolarised xenon
25th May 20217:00 amRNSConference attendance at Mello
17th May 20217:00 amRNSExercise of warrants
14th May 20219:30 amRNSConference attendances
10th May 20217:00 amRNSNew system order
4th May 202111:06 amRNSSecond Price Monitoring Extn
4th May 202111:00 amRNSPrice Monitoring Extension
16th Apr 202110:01 amRNSExercise of warrants
6th Apr 20213:05 pmRNSResult of General Meeting
6th Apr 20217:00 amRNSResult of Open Offer
1st Apr 20214:52 pmRNSTotal Voting Rights
29th Mar 20217:00 amRNSInvestor presentation
25th Mar 20217:00 amRNSExercise of Warrants
17th Mar 20217:00 amRNSInvestment in Polarean Imaging plc
16th Mar 20215:36 pmRNSPublication of Circular and Notice of GM
16th Mar 20217:00 amRNSResult of Placing and Subscription, PDMR Dealings
15th Mar 20215:50 pmRNSProposed Placing, Subscription and Open Offer
24th Feb 20217:00 amRNSExercise of Warrants
22nd Feb 20217:00 amRNSBoard appointment
25th Jan 20217:00 amRNSChange of Nominated Adviser
8th Jan 20212:05 pmRNSSecond Price Monitoring Extn
8th Jan 20212:01 pmRNSPrice Monitoring Extension
23rd Dec 20204:40 pmRNSSecond Price Monitoring Extn
23rd Dec 20204:35 pmRNSPrice Monitoring Extension
23rd Dec 20207:00 amRNSFDA acceptance for filing of New Drug Application
4th Dec 20207:00 amRNSAppointment of Joint Corporate Broker
1st Dec 20204:41 pmRNSSecond Price Monitoring Extn
1st Dec 20204:36 pmRNSPrice Monitoring Extension
1st Dec 20202:06 pmRNSSecond Price Monitoring Extn
1st Dec 20202:01 pmRNSPrice Monitoring Extension
1st Dec 202011:05 amRNSSecond Price Monitoring Extn
1st Dec 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.